The increase in circulating FGF21 levels might also reflect a protective compensatory response to insulin resistance, hyperlipidemia, and the increase in systemic inflammation in patients with atherosclerotic diseases [34]. This evidence concerns the gene FGF21 and hyperlipidemia.